首页 > 最新文献

Journal of substance use and addiction treatment最新文献

英文 中文
Parent SMART: Effects of residential treatment and an adjunctive parenting intervention on behavioral health services utilization. Parent SMART:住院治疗和辅助育儿干预对行为健康服务使用的影响。
N/A PSYCHOLOGY, CLINICAL Pub Date : 2024-11-01 Epub Date: 2024-05-16 DOI: 10.1016/j.josat.2024.209399
Sara J Becker, Tim Janssen, Hannah Shiller, Emily DiBartolo, Yiqing Fan, Timothy Souza, Lourah M Kelly, Sarah A Helseth

Introduction: Scant research has examined the impact of residential treatment on adolescent behavioral healthcare utilization post-discharge, even though behavioral healthcare utilization is major driver of healthcare costs. In the primary analyses of a pilot randomized trial, Parent SMART - a technology-assisted intervention for parents of adolescents in residential treatment - was found to improve parental monitoring and parent-adolescent communication, reduce adolescent drinking, and reduce adolescent school-related problems, relative to residential treatment as usual (TAU). The goal of this secondary analysis of the pilot randomized trial was to assess the effects of residential treatment and the adjunctive Parent SMART intervention on both the amount and type of subsequent behavioral healthcare utilization.

Method: The study randomized sixty-one parent-adolescent dyads to residential TAU (n = 31) or residential TAU plus Parent SMART (n = 30). Of the 61 dyads, 37 were recruited from a short-term residential facility and 24 were recruited from a long-term facility. Adolescents completed a structured clinical interview and self-reported their behavioral health-related visits to the emergency department, nights in residential/inpatient, and outpatient visits over the past 90 days, at baseline, 12-, and 24-weeks post-discharge. Generalized linear mixed models (GLMMs) examined both linear and non-linear (pre- to post- residential treatment) trends, pooled, and stratified by residential facility to examine behavioral health service utilization.

Results: Both the linear and pre-post GLMMs revealed that behavioral health-related emergency department visits and residential/inpatient nights decreased across both residential facilities. GLMMs estimating change from the pre- to post period indicated that outpatient visits increased across both facilities. There were no significant effects of the Parent SMART adjunctive intervention in GLMMs, though bivariate tests and the direction of effects signaled that Parent SMART was associated with more nights of residential/inpatient utilization.

Conclusion: Residential substance use treatment may reduce adolescents' subsequent utilization of costly behavioral healthcare services such as emergency department visits and residential/inpatient nights, while increasing utilization of outpatient services. Parent SMART was not associated with significant changes in behavioral healthcare utilization, but the pattern of results was consistent with prior literature suggesting that stronger parenting skills are associated with greater utilization of non-emergency services.

简介:尽管行为医疗是医疗成本的主要驱动因素,但很少有研究探讨住院治疗对青少年出院后行为医疗使用的影响。在一项试点随机试验的主要分析中发现,与住院治疗照常进行(TAU)相比,Parent SMART(一种针对住院治疗青少年家长的技术辅助干预措施)能改善家长对青少年的监督和家长与青少年之间的沟通,减少青少年酗酒,并减少青少年与学校相关的问题。此次对试点随机试验进行二次分析的目的是评估住院治疗和辅助性家长 SMART 干预对后续行为医疗使用的数量和类型的影响:该研究将61对父母-青少年组合随机分配到寄宿TAU(31人)或寄宿TAU加家长SMART(30人)。在这61对组合中,37对来自短期寄宿机构,24对来自长期寄宿机构。青少年完成了结构化临床访谈,并在基线、出院后 12 周和 24 周自我报告了过去 90 天内与行为健康相关的急诊就诊、住宿/住院天数和门诊就诊情况。广义线性混合模型(GLMMs)对线性和非线性(住院治疗前到住院治疗后)趋势进行了研究,并按住院设施进行了汇总和分层,以检查行为健康服务的使用情况:结果:线性和前后 GLMM 均显示,与行为健康相关的急诊就诊率和住宿/住院天数在两个住宿设施中均有所下降。估算前后变化的 GLMM 表明,两家机构的门诊量均有所增加。在GLMMs中,家长SMART辅助干预没有明显的效果,但双变量测试和效果方向表明,家长SMART与更多的住院/住院天数有关:结论:住院药物使用治疗可减少青少年随后使用昂贵的行为医疗服务,如急诊就诊和住院/住院天数,同时增加门诊服务的使用。家长 SMART 与行为医疗服务利用率的显著变化无关,但其结果模式与之前的文献一致,即更强的养育技能与非急诊服务利用率的增加有关。
{"title":"Parent SMART: Effects of residential treatment and an adjunctive parenting intervention on behavioral health services utilization.","authors":"Sara J Becker, Tim Janssen, Hannah Shiller, Emily DiBartolo, Yiqing Fan, Timothy Souza, Lourah M Kelly, Sarah A Helseth","doi":"10.1016/j.josat.2024.209399","DOIUrl":"10.1016/j.josat.2024.209399","url":null,"abstract":"<p><strong>Introduction: </strong>Scant research has examined the impact of residential treatment on adolescent behavioral healthcare utilization post-discharge, even though behavioral healthcare utilization is major driver of healthcare costs. In the primary analyses of a pilot randomized trial, Parent SMART - a technology-assisted intervention for parents of adolescents in residential treatment - was found to improve parental monitoring and parent-adolescent communication, reduce adolescent drinking, and reduce adolescent school-related problems, relative to residential treatment as usual (TAU). The goal of this secondary analysis of the pilot randomized trial was to assess the effects of residential treatment and the adjunctive Parent SMART intervention on both the amount and type of subsequent behavioral healthcare utilization.</p><p><strong>Method: </strong>The study randomized sixty-one parent-adolescent dyads to residential TAU (n = 31) or residential TAU plus Parent SMART (n = 30). Of the 61 dyads, 37 were recruited from a short-term residential facility and 24 were recruited from a long-term facility. Adolescents completed a structured clinical interview and self-reported their behavioral health-related visits to the emergency department, nights in residential/inpatient, and outpatient visits over the past 90 days, at baseline, 12-, and 24-weeks post-discharge. Generalized linear mixed models (GLMMs) examined both linear and non-linear (pre- to post- residential treatment) trends, pooled, and stratified by residential facility to examine behavioral health service utilization.</p><p><strong>Results: </strong>Both the linear and pre-post GLMMs revealed that behavioral health-related emergency department visits and residential/inpatient nights decreased across both residential facilities. GLMMs estimating change from the pre- to post period indicated that outpatient visits increased across both facilities. There were no significant effects of the Parent SMART adjunctive intervention in GLMMs, though bivariate tests and the direction of effects signaled that Parent SMART was associated with more nights of residential/inpatient utilization.</p><p><strong>Conclusion: </strong>Residential substance use treatment may reduce adolescents' subsequent utilization of costly behavioral healthcare services such as emergency department visits and residential/inpatient nights, while increasing utilization of outpatient services. Parent SMART was not associated with significant changes in behavioral healthcare utilization, but the pattern of results was consistent with prior literature suggesting that stronger parenting skills are associated with greater utilization of non-emergency services.</p>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“Yeah, this is not going to work for me”–The impact of federal policy restrictions on methadone continuation upon release from jail or prison "是的,这对我没用"--联邦政策对出狱后继续服用美沙酮的限制所产生的影响。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-10 DOI: 10.1016/j.josat.2024.209538

Introduction

Individuals impacted by the criminal-legal system face increased risk of opioid overdose. Medications for opioid use disorder (MOUD) provide a life-saving intervention. Multiple barriers prevent access to MOUD, including federal policies regulating opioid treatment programs (OTPs). This study aims to identify how federal policy affects anticipated barriers to methadone treatment access at a high-risk time for opioid mortality: community re-entry after incarceration.

Methods

The study used standard qualitative methods to conduct 40 in-depth-interviews with incarcerated individuals enrolled in the Rhode Island Department of Corrections MOUD treatment program. Semi-structured interviews took place between June and August 2018 and focused on participants' experiences with MOUD and anticipated treatment barriers upon re-entry. A deductive coding framework incorporating the SAMHSA “8-point” criteria for take-home methadone as the a priori codebook and additional identified barriers informed further inductive analysis.

Results

Four themes emerged: (1) logistical hurdles such as transportation and clinic location impeded clinic access; (2) punitive measures within clinics, like dose reduction for rule infractions, discouraged treatment continuation; (3) the environment of methadone clinics often tempted return to use; (4) while the structured nature of methadone treatment provided accountability, it also posed challenges. Federal policies, particularly around daily dosing and “take-home” regulations, exacerbated barriers for those re-entering the community. State and clinic level policies, however, were also identified as direct or exacerbating barriers to treatment access.

Conclusion

Significant hurdles persist for methadone access among individuals released from incarceration. Though the federal 8-point criteria have now been replaced with more flexible take-home policies, our findings highlight critical treatment barriers for individuals during the high-risk period of community re-entry. State and clinic level policies also exacerbate many of the barrier-driven themes identified in this analysis. Future work can explore how to best implement the identified benefits of a structured program without forcing the punitive measures that discourage treatment retention. Additional policy reform can help mitigate the effects of other social determinants of health (including transportation access). Ultimately, the many barriers to community methadone treatment retention also apply to individuals involved in the criminal legal system; they can be exacerbated at the federal, state, and clinic policy level.
导言:受刑事法律系统影响的个人面临阿片类药物过量的风险增加。治疗阿片类药物使用障碍(MOUD)的药物是一种挽救生命的干预措施。多种障碍阻碍了阿片类药物的使用,包括联邦政策对阿片类药物治疗项目(OTPs)的监管。本研究旨在确定联邦政策如何影响阿片类药物死亡高危期美沙酮治疗的预期障碍:监禁后重返社区:本研究采用标准的定性方法,对参加罗德岛惩教署 MOUD 治疗项目的在押人员进行了 40 次深入访谈。半结构式访谈于 2018 年 6 月至 8 月间进行,重点关注参与者参与 MOUD 的经历以及重返社会后的预期治疗障碍。一个演绎编码框架将美国卫生与健康服务协会(SAMHSA)带回家的美沙酮 "8 点 "标准作为先验编码手册,并将其他已确定的障碍纳入进一步的归纳分析:出现了四个主题:(1) 交通和诊所位置等后勤障碍阻碍了患者进入诊所;(2) 诊所内的惩罚性措施,如违规减量,阻碍了治疗的继续;(3) 美沙酮诊所的环境往往诱使患者重新使用美沙酮;(4) 虽然美沙酮治疗的结构性提供了问责制,但也带来了挑战。联邦政策,特别是关于每日剂量和 "带回家 "的规定,加剧了那些重返社区者的障碍。然而,州和诊所层面的政策也被认为是获得治疗的直接障碍或加剧障碍:结论:刑满释放人员在获得美沙酮治疗方面仍然存在重大障碍。尽管联邦的 8 点标准现已被更灵活的带回家政策所取代,但我们的研究结果还是强调了个人在重返社区的高风险时期所面临的关键治疗障碍。州和诊所层面的政策也加剧了本次分析中发现的许多障碍驱动型主题。未来的工作可以探索如何在不强制采取惩罚性措施的情况下,最好地实施已确定的结构化计划的益处,这些措施会阻碍治疗的持续进行。其他政策改革也有助于减轻其他健康社会决定因素(包括交通便利性)的影响。归根结底,社区美沙酮治疗的许多障碍也适用于涉及刑事法律系统的个人;联邦、州和诊所的政策层面都会加剧这些障碍。
{"title":"“Yeah, this is not going to work for me”–The impact of federal policy restrictions on methadone continuation upon release from jail or prison","authors":"","doi":"10.1016/j.josat.2024.209538","DOIUrl":"10.1016/j.josat.2024.209538","url":null,"abstract":"<div><h3>Introduction</h3><div>Individuals impacted by the criminal-legal system face increased risk of opioid overdose. Medications for opioid use disorder (MOUD) provide a life-saving intervention. Multiple barriers prevent access to MOUD, including federal policies regulating opioid treatment programs (OTPs). This study aims to identify how federal policy affects anticipated barriers to methadone treatment access at a high-risk time for opioid mortality: community re-entry after incarceration.</div></div><div><h3>Methods</h3><div>The study used standard qualitative methods to conduct 40 in-depth-interviews with incarcerated individuals enrolled in the Rhode Island Department of Corrections MOUD treatment program. Semi-structured interviews took place between June and August 2018 and focused on participants' experiences with MOUD and anticipated treatment barriers upon re-entry. A deductive coding framework incorporating the SAMHSA “8-point” criteria for take-home methadone as the <em>a priori</em> codebook and additional identified barriers informed further inductive analysis.</div></div><div><h3>Results</h3><div>Four themes emerged: (1) logistical hurdles such as transportation and clinic location impeded clinic access; (2) punitive measures within clinics, like dose reduction for rule infractions, discouraged treatment continuation; (3) the environment of methadone clinics often tempted return to use; (4) while the structured nature of methadone treatment provided accountability, it also posed challenges. Federal policies, particularly around daily dosing and “take-home” regulations, exacerbated barriers for those re-entering the community. State and clinic level policies, however, were also identified as direct or exacerbating barriers to treatment access.</div></div><div><h3>Conclusion</h3><div>Significant hurdles persist for methadone access among individuals released from incarceration. Though the federal 8-point criteria have now been replaced with more flexible take-home policies, our findings highlight critical treatment barriers for individuals during the high-risk period of community re-entry. State and clinic level policies also exacerbate many of the barrier-driven themes identified in this analysis. Future work can explore how to best implement the identified benefits of a structured program without forcing the punitive measures that discourage treatment retention. Additional policy reform can help mitigate the effects of other social determinants of health (including transportation access). Ultimately, the many barriers to community methadone treatment retention also apply to individuals involved in the criminal legal system; they can be exacerbated at the federal, state, and clinic policy level.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors affecting problem-solving court team decisions about medications for opioid use disorder 影响问题解决法庭小组就阿片类药物使用障碍的药物治疗做出决定的因素。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-09 DOI: 10.1016/j.josat.2024.209525

Background

Problem-solving courts (PSCs) provide alternatives to prosecution and incarceration for drug-related crimes and offer integrated support for people who have lost custody of children due to drug use. Methadone and buprenorphine are lifesaving medications for opioid use disorder (MOUD) but are underused by PSC clients. Even when PSCs lack a court-level prohibition against MOUD, court staff still make individualized decisions about whether a court client can use MOUD. Therefore, we sought to identify factors involved in such individualized PSC court decisions about clients' use of MOUD.

Methods

We conducted semi-structured interviews and focus groups between Summer and Fall 2022 with a convenience sample of 54 PSC staff members from 33 courts across four states. Data were analyzed using iterative categorization.

Results

Interviewees indicated that their courts had eliminated blanket prohibitions against MOUD due to federal and state policy funding requirements, widespread dissemination of voluntary best practice standards, fear of lawsuits, and MOUD education targeting courts. Courts allowed MOUD if the court client accessed it through a treatment provider with whom the court collaborates. Some courts only allowed court clients to access MOUD from non-partnering treatment providers after a court-led “vetting” process of the proposed MOUD provider. MOUD provider characteristics considered during the vetting process included the provider's willingness to communicate with the court, frequent drug testing, adjustments of medication or dosage in response to aberrant results, offering of counseling, and acceptance of Medicaid or sliding scale payments. PSC staff were least comfortable with court clients using methadone treatment.

Conclusions

The presence (or lack of) a PSC-MOUD partnership is a key factor involved in court staff decisions when a court client desires MOUD. Therefore, increasing the number of partnerships between PSCs and MOUD providers could lead to higher rates of MOUD utilization. It is unclear whether court-led vetting processes for non-partnering MOUD treatment providers are necessary or appropriate, and such vetting processes could reduce treatment choice or access in communities with few MOUD providers.
背景:问题解决法庭(PSCs)为与毒品有关的犯罪提供起诉和监禁的替代方案,并为因吸毒而失去子女监护权的人提供综合支持。美沙酮和丁丙诺啡是治疗阿片类药物使用障碍 (MOUD) 的救命药物,但 PSC 服务对象对其使用不足。即使 PSC 没有在法院层面禁止使用 MOUD,法院工作人员仍会根据个人情况决定法院客户是否可以使用 MOUD。因此,我们试图找出私营军事服务公司的法庭在决定客户使用 MOUD 时所涉及的个性化因素:2022 年夏季至秋季,我们对来自 4 个州 33 个法院的 54 名 PSC 工作人员进行了半结构化访谈和焦点小组讨论。我们采用迭代分类法对数据进行了分析:受访者表示,由于联邦和州政策的资金要求、自愿性最佳实践标准的广泛传播、对诉讼的恐惧以及针对法院的 MOUD 教育,他们的法院已经取消了对 MOUD 的全面禁止。如果法院委托人通过与法院合作的治疗机构获得 MOUD,法院则允许 MOUD。一些法院只允许法院委托人在经过法院主导的 "审查 "程序后,从非合作治疗提供方获得MOUD。审查过程中考虑的 "谅解备忘录 "提供者的特征包括提供者是否愿意与法院沟通、是否经常进行药物检测、是否针对异常结果调整药物或剂量、是否提供咨询、是否接受医疗补助或按比例付款。PSC 工作人员最不喜欢法院客户使用美沙酮治疗:当法院服务对象希望接受美沙酮治疗时,是否存在(或缺乏)社区服务中心与美沙酮治疗机构之间的合作关系是法院工作人员做出决定的关键因素。因此,增加私营服刑中心与美沙酮治疗提供者之间的合作关系可能会提高美沙酮治疗的使用率。目前尚不清楚,由法院主导的对非合作的 "谅解备忘录 "治疗提供者的审查程序是否必要或适当,在 "谅解备忘录 "提供者较少的社区,这种审查程序可能会减少治疗选择或治疗机会。
{"title":"Factors affecting problem-solving court team decisions about medications for opioid use disorder","authors":"","doi":"10.1016/j.josat.2024.209525","DOIUrl":"10.1016/j.josat.2024.209525","url":null,"abstract":"<div><h3>Background</h3><div>Problem-solving courts (PSCs) provide alternatives to prosecution and incarceration for drug-related crimes and offer integrated support for people who have lost custody of children due to drug use. Methadone and buprenorphine are lifesaving medications for opioid use disorder (MOUD) but are underused by PSC clients. Even when PSCs lack a court-level prohibition against MOUD, court staff still make individualized decisions about whether a court client can use MOUD. Therefore, we sought to identify factors involved in such individualized PSC court decisions about clients' use of MOUD.</div></div><div><h3>Methods</h3><div>We conducted semi-structured interviews and focus groups between Summer and Fall 2022 with a convenience sample of 54 PSC staff members from 33 courts across four states. Data were analyzed using iterative categorization.</div></div><div><h3>Results</h3><div>Interviewees indicated that their courts had eliminated blanket prohibitions against MOUD due to federal and state policy funding requirements, widespread dissemination of voluntary best practice standards, fear of lawsuits, and MOUD education targeting courts. Courts allowed MOUD if the court client accessed it through a treatment provider with whom the court collaborates. Some courts only allowed court clients to access MOUD from non-partnering treatment providers after a court-led “vetting” process of the proposed MOUD provider. MOUD provider characteristics considered during the vetting process included the provider's willingness to communicate with the court, frequent drug testing, adjustments of medication or dosage in response to aberrant results, offering of counseling, and acceptance of Medicaid or sliding scale payments. PSC staff were least comfortable with court clients using methadone treatment.</div></div><div><h3>Conclusions</h3><div>The presence (or lack of) a PSC-MOUD partnership is a key factor involved in court staff decisions when a court client desires MOUD. Therefore, increasing the number of partnerships between PSCs and MOUD providers could lead to higher rates of MOUD utilization. It is unclear whether court-led vetting processes for non-partnering MOUD treatment providers are necessary or appropriate, and such vetting processes could reduce treatment choice or access in communities with few MOUD providers.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A community-academic partnership to develop an implementation support package for overdose prevention in permanent supportive housing 社区与学术界合作,为在永久性支持性住房中预防用药过量制定一揽子实施支持计划。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-09 DOI: 10.1016/j.josat.2024.209533

Introduction

The overdose crisis in the U.S. disproportionately impacts people experiencing homelessness. Permanent supportive housing (PSH) – permanent, affordable housing with voluntary support services – is an effective, evidence-based intervention to address homelessness. However, overdose risk remains high even after entering PSH for individual and structural reasons. In this study, we aimed to refine a set of evidence-based overdose prevention practices (EBPs) and an associated implementation support package for PSH settings using focus groups with PSH tenants, frontline staff, and leaders.

Methods

Our community-academic team identified an initial set of overdose EBPs applicable for PSH through research, public health guidance, and a needs assessment. We adapted these practices based on feedback from focus groups with PSH leaders, staff, and tenants. Focus groups followed semi-structured interview guides developed using the EPIS (Exploration, Preparation, Implementation, Sustainment) framework constructs of inner context, outer context, and bridging factors related to overdose prevention and response.

Results

We conducted 16 focus groups with 40 unique participants (14 PSH tenants, 15 PSH staff, 11 PSH leaders); focus groups were held in two iterative rounds and individuals could participate in one or both rounds. Participants were diverse in gender, race, and ethnicity. Focus group participants were enthusiastic about the proposed EBPs and implementation strategies, while contributing unique insights and concrete suggestions to improve upon them. The implementation support package contains an iteratively refined PSH Overdose Prevention (POP) Toolkit with 20 EBPs surrounding overdose prevention and response, harm reduction, and support for substance use treatment and additional core implementation strategies including practice facilitation, tenant-staff champion teams, and learning collaboratives.

Conclusions

This manuscript describes how robust community-academic partnerships and input from people with lived experience as tenants and staff in PSH informed adaptation of evidence-based overdose prevention approaches and implementation strategies to improve their fit for PSH settings. This effort can inform similar efforts nationally in other settings serving highly marginalized populations. We are currently conducting a randomized trial of the refined overdose prevention implementation support package in PSH.
导言:美国的用药过量危机对无家可归者的影响尤为严重。永久性支持性住房(Permanent supportive housing,PSH)--提供自愿支持服务的永久性经济适用房--是解决无家可归问题的一种有效、循证的干预措施。然而,由于个人原因和结构性原因,即使进入了永久支持性住房,用药过量的风险仍然很高。在这项研究中,我们旨在通过与 PSH 租户、一线员工和领导者进行焦点小组讨论,完善一套基于证据的用药过量预防实践(EBPs)和相关的 PSH 环境实施支持包:我们的社区-学术团队通过研究、公共卫生指导和需求评估,初步确定了一套适用于私人住宅的用药过量 EBPs。我们根据 PSH 领导者、员工和租户的焦点小组反馈,对这些做法进行了调整。焦点小组遵循半结构式访谈指南,该指南采用 EPIS(探索、准备、实施、维持)框架结构,即与用药过量预防和应对相关的内在环境、外在环境和衔接因素:我们进行了 16 次焦点小组讨论,共有 40 人参加(14 名 PSH 租户、15 名 PSH 工作人员、11 名 PSH 领导);焦点小组讨论分两轮进行,个人可参加其中一轮或两轮。参与者在性别、种族和民族方面具有多样性。焦点小组参与者对建议的 EBPs 和实施策略充满热情,同时提出了独特的见解和具体的改进建议。实施支持包包含一个经过反复改进的 PSH 药物过量预防(POP)工具包,其中有 20 个 EBPs,分别围绕药物过量预防和响应、减少伤害、支持药物使用治疗以及其他核心实施策略,包括实践促进、租户-员工冠军团队和学习合作:这篇手稿描述了如何建立强大的社区-学术合作伙伴关系,以及如何根据具有 PSH 租户和工作人员生活经验的人的意见,调整基于证据的吸毒过量预防方法和实施策略,使其更加适合 PSH 环境。这项工作可以为全国范围内为高度边缘化人群提供服务的其他环境中的类似工作提供参考。目前,我们正在对 PSH 中改进后的吸毒过量预防实施支持包进行随机试验。
{"title":"A community-academic partnership to develop an implementation support package for overdose prevention in permanent supportive housing","authors":"","doi":"10.1016/j.josat.2024.209533","DOIUrl":"10.1016/j.josat.2024.209533","url":null,"abstract":"<div><h3>Introduction</h3><div>The overdose crisis in the U.S. disproportionately impacts people experiencing homelessness. Permanent supportive housing (PSH) – permanent, affordable housing with voluntary support services – is an effective, evidence-based intervention to address homelessness. However, overdose risk remains high even after entering PSH for individual and structural reasons. In this study, we aimed to refine a set of evidence-based overdose prevention practices (EBPs) and an associated implementation support package for PSH settings using focus groups with PSH tenants, frontline staff, and leaders.</div></div><div><h3>Methods</h3><div>Our community-academic team identified an initial set of overdose EBPs applicable for PSH through research, public health guidance, and a needs assessment. We adapted these practices based on feedback from focus groups with PSH leaders, staff, and tenants. Focus groups followed semi-structured interview guides developed using the EPIS (Exploration, Preparation, Implementation, Sustainment) framework constructs of inner context, outer context, and bridging factors related to overdose prevention and response.</div></div><div><h3>Results</h3><div>We conducted 16 focus groups with 40 unique participants (14 PSH tenants, 15 PSH staff, 11 PSH leaders); focus groups were held in two iterative rounds and individuals could participate in one or both rounds. Participants were diverse in gender, race, and ethnicity. Focus group participants were enthusiastic about the proposed EBPs and implementation strategies, while contributing unique insights and concrete suggestions to improve upon them. The implementation support package contains an iteratively refined PSH Overdose Prevention (POP) Toolkit with 20 EBPs surrounding overdose prevention and response, harm reduction, and support for substance use treatment and additional core implementation strategies including practice facilitation, tenant-staff champion teams, and learning collaboratives.</div></div><div><h3>Conclusions</h3><div>This manuscript describes how robust community-academic partnerships and input from people with lived experience as tenants and staff in PSH informed adaptation of evidence-based overdose prevention approaches and implementation strategies to improve their fit for PSH settings. This effort can inform similar efforts nationally in other settings serving highly marginalized populations. We are currently conducting a randomized trial of the refined overdose prevention implementation support package in PSH.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is naloxone where it needs to be? Using spatial analytics to examine equitable distribution of community-based naloxone sites 纳洛酮在哪里?利用空间分析技术检查社区纳洛酮站点的公平分布情况。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-09 DOI: 10.1016/j.josat.2024.209530

Background

One of the most effective harm reduction services for preventing opioid overdose deaths is naloxone. Given the ongoing opioid crisis, which has led to a surge in overdose deaths across the country, expanding access to naloxone is critical. Community-based naloxone distributions sites in Palm Beach County can increase access to naloxone. However, several rural and disadvantaged regions rarely have any type of access to naloxone. The purpose of this descriptive paper is to examine the spatial distribution of and evaluate equitable accessibility to community-based naloxone sites in Palm Beach County.

Methods

We examined health equity in the distribution of community-based naloxone sites using a mixed-methods approach with ArcGIS Pro version 3.0, which is a geographic information system (GIS) software used for mapping, spatial analysis, and data visualization.

Results

The Belle Glade region was identified as the location most adversely affected with health inequities and limited accessibility to naloxone distribution sites, as it ranked in the 100 % percentile for all social vulnerability index (SVI) themes. The 30-minute drive-time area calculated a county service area of 1885.3 km2 (km2), which covers about 34 % of the 478.0 km2 land area of census tracts. Drive-time areas did not account for periods of heavier traffic such as during rush hour. Maximum distances during heavier traffic may be smaller, thus decreasing accessibility to naloxone distribution sites.

Conclusion

There is a need for effective policy-led strategies tailored to expanding our understanding of the challenges that are experienced by the individuals in need of naloxone and encountered by the distribution sites themselves, as accessible naloxone is crucial for preventing nonfatal and fatal overdoses and ensuring timely emergency responses in vulnerable communities.
背景:纳洛酮是预防阿片类药物过量致死最有效的减低伤害服务之一。鉴于持续的阿片类药物危机已导致全国范围内用药过量死亡人数激增,扩大纳洛酮的使用范围至关重要。棕榈滩县以社区为基础的纳洛酮分发点可以增加纳洛酮的获取途径。然而,一些农村和贫困地区很少有机会获得纳洛酮。这篇描述性论文旨在研究棕榈滩县社区纳洛酮发放点的空间分布情况,并评估其公平性:方法:我们使用 ArcGIS Pro 3.0 版(一款地理信息系统 (GIS) 软件,用于制图、空间分析和数据可视化),采用混合方法研究了社区纳洛酮站点分布的健康公平性:贝勒格莱德地区被确定为受健康不平等和纳洛酮分发点交通不便影响最严重的地区,因为该地区在所有社会脆弱性指数(SVI)主题中的排名均在百分位数之上。30 分钟车程区域计算出的县级服务区面积为 1885.3 平方公里,约占人口普查区 478.0 平方公里土地面积的 34%。驾车时间区域没有考虑交通高峰期等交通繁忙时段。交通繁忙时的最大距离可能较小,从而降低了纳洛酮分发点的可达性:有必要制定有效的政策导向战略,以扩大我们对需要纳洛酮的人所经历的挑战以及分发点本身所遇到的挑战的了解,因为方便使用纳洛酮对于防止非致命和致命过量用药以及确保在脆弱社区及时采取应急措施至关重要。
{"title":"Is naloxone where it needs to be? Using spatial analytics to examine equitable distribution of community-based naloxone sites","authors":"","doi":"10.1016/j.josat.2024.209530","DOIUrl":"10.1016/j.josat.2024.209530","url":null,"abstract":"<div><h3>Background</h3><div>One of the most effective harm reduction services for preventing opioid overdose deaths is naloxone. Given the ongoing opioid crisis, which has led to a surge in overdose deaths across the country, expanding access to naloxone is critical. Community-based naloxone distributions sites in Palm Beach County can increase access to naloxone. However, several rural and disadvantaged regions rarely have any type of access to naloxone. The purpose of this descriptive paper is to examine the spatial distribution of and evaluate equitable accessibility to community-based naloxone sites in Palm Beach County.</div></div><div><h3>Methods</h3><div>We examined health equity in the distribution of community-based naloxone sites using a mixed-methods approach with ArcGIS Pro version 3.0, which is a geographic information system (GIS) software used for mapping, spatial analysis, and data visualization.</div></div><div><h3>Results</h3><div>The Belle Glade region was identified as the location most adversely affected with health inequities and limited accessibility to naloxone distribution sites, as it ranked in the 100 % percentile for all social vulnerability index (SVI) themes. The 30-minute drive-time area calculated a county service area of 1885.3 km<sup>2</sup> (km<sup>2</sup>), which covers about 34 % of the 478.0 km<sup>2</sup> land area of census tracts. Drive-time areas did not account for periods of heavier traffic such as during rush hour. Maximum distances during heavier traffic may be smaller, thus decreasing accessibility to naloxone distribution sites.</div></div><div><h3>Conclusion</h3><div>There is a need for effective policy-led strategies tailored to expanding our understanding of the challenges that are experienced by the individuals in need of naloxone and encountered by the distribution sites themselves, as accessible naloxone is crucial for preventing nonfatal and fatal overdoses and ensuring timely emergency responses in vulnerable communities.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contextual factors associated with successful alcohol screening and brief intervention implementation and sustainment in adult primary care 在成人初级保健中成功实施和维持酒精筛查和简短干预的相关背景因素。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-08 DOI: 10.1016/j.josat.2024.209532

Introduction

Hazardous drinking is a public health problem affecting approximately 20 % of the U.S. primary care population. Clinical trials have documented the efficacy and effectiveness of Alcohol Screening and Brief Intervention (ASBI), yet widespread implementation remains elusive, and questions remain regarding optimal implementation and sustainment strategies. Kaiser Permanente Northern California (KPNC) implemented systematic ASBI in adult primary care in mid-2013. We used 8 years of electronic health record (EHR) data, combined with surveys which captured primary care provider perceptions organized into PRISM (Practical, Robust Implementation and Sustainability Model) implementation framework domains (Intervention, External Environment, Implementation Infrastructure, and Recipients), to characterize ASBI implementation and sustainment and test how various factors are associated with ASBI rates.

Methods

Using EHR data, we calculated yearly screening rates of adults with a primary care visit, and brief intervention (BI) rates among those with a positive hazardous drinking screen, (exceeding the age and sex-specific daily and weekly low-risk NIH guidelines (≤3 per day and ≤ 7 per week for women and older men; ≤4 per day and ≤ 14 per week for men 18–65)), across KPNC, from 2014 to 2021. We collected web-based survey data, informed by the PRISM domains, from primary care providers (n = 796; 35.5 % RR) to assess perceptions on ASBI implementation and sustainability.

Results

Between 1/1/2014 and 12/31/21 there were 5,072,270 completed screenings and 624,167 BIs. After adjusting for patient panel characteristics, we found that facilities with higher Implementation Infrastructure domain scores, indicating more robust implementation capacity, had higher screening and BI rates; facilities with higher Intervention domain scores, indicating positive perceptions of SBIRT evidence, and facilities with higher Recipients domain scores, indicating perceived organizational robustness, clinician culture and management support; and greater perceived patient needs and their likely benefit from SBIRT, had higher BI rates.

Conclusions

Results provide information on factors which may facilitate successful ASBI implementation and sustainability and could inform future ASBI implementation efforts in healthcare system settings. In particular, efforts toward bolstering an organization's implementation infrastructure capacity, prior to embarking on implementation of a systematic ASBI program, could potentially help pave the way for successful implementation.
导言:有害饮酒是一个公共卫生问题,影响着约 20% 的美国初级保健人群。临床试验证明了酒精筛查和简单干预(ASBI)的效果和有效性,但广泛实施仍然遥遥无期,有关最佳实施和持续策略的问题依然存在。北加州凯泽医疗集团(KPNC)于 2013 年年中在成人初级保健中实施了系统的 ASBI。我们使用了 8 年的电子健康记录(EHR)数据,结合按 PRISM(实用、稳健的实施和可持续发展模式)实施框架领域(干预、外部环境、实施基础设施和接受者)划分的基层医疗服务提供者看法调查,来描述 ASBI 的实施和可持续发展情况,并检验各种因素与 ASBI 发生率之间的关联:利用电子病历数据,我们计算了 2014 年至 2021 年期间 KPNC 的成人初级保健年筛查率,以及危险饮酒筛查阳性者的简短干预率(超过特定年龄和性别的每日和每周低风险 NIH 指南(女性和老年男性每日≤3 次,每周≤7 次;18-65 岁男性每日≤4 次,每周≤14 次))。我们从初级保健提供者(n = 796;35.5 % RR)处收集了基于 PRISM 领域的网络调查数据,以评估对 ASBI 实施和可持续性的看法:从 2014 年 1 月 1 日至 21 年 12 月 31 日,共完成了 5,072,270 次筛查和 624,167 次 BI。在对患者面板特征进行调整后,我们发现,实施基础设施领域得分较高的机构(表明实施能力较强),筛查率和BI率较高;干预领域得分较高的机构(表明对SBIRT证据的积极看法),以及接受者领域得分较高的机构(表明感知到的组织稳健性、临床医生文化和管理支持),以及感知到的患者需求较大且可能从SBIRT中获益的机构,BI率较高:结论:研究结果提供了有关促进 ASBI 成功实施和可持续发展的因素的信息,可为今后在医疗系统环境中实施 ASBI 提供参考。特别是,在开始实施系统化的 ASBI 计划之前,努力加强组织的实施基础设施能力可能有助于为成功实施铺平道路。
{"title":"Contextual factors associated with successful alcohol screening and brief intervention implementation and sustainment in adult primary care","authors":"","doi":"10.1016/j.josat.2024.209532","DOIUrl":"10.1016/j.josat.2024.209532","url":null,"abstract":"<div><h3>Introduction</h3><div>Hazardous drinking is a public health problem affecting approximately 20 % of the U.S. primary care population. Clinical trials have documented the efficacy and effectiveness of Alcohol Screening and Brief Intervention (ASBI), yet widespread implementation remains elusive, and questions remain regarding optimal implementation and sustainment strategies. Kaiser Permanente Northern California (KPNC) implemented systematic ASBI in adult primary care in mid-2013. We used 8 years of electronic health record (EHR) data, combined with surveys which captured primary care provider perceptions organized into PRISM (<em>Practical, Robust Implementation and Sustainability Model</em>) implementation framework domains (Intervention, External Environment, Implementation Infrastructure, and Recipients), to characterize ASBI implementation and sustainment and test how various factors are associated with ASBI rates.</div></div><div><h3>Methods</h3><div>Using EHR data, we calculated yearly screening rates of adults with a primary care visit, and brief intervention (BI) rates among those with a positive hazardous drinking screen, (exceeding the age and sex-specific daily and weekly low-risk NIH guidelines (≤3 per day and ≤ 7 per week for women and older men; ≤4 per day and ≤ 14 per week for men 18–65)), across KPNC, from 2014 to 2021. We collected web-based survey data, informed by the PRISM domains, from primary care providers (<em>n</em> = 796; 35.5 % RR) to assess perceptions on ASBI implementation and sustainability.</div></div><div><h3>Results</h3><div>Between 1/1/2014 and 12/31/21 there were 5,072,270 completed screenings and 624,167 BIs. After adjusting for patient panel characteristics, we found that facilities with higher <em>Implementation Infrastructure</em> domain scores, indicating more robust implementation capacity, had higher screening and BI rates; facilities with higher <em>Intervention</em> domain scores, indicating positive perceptions of SBIRT evidence, and facilities with higher <em>Recipients</em> domain scores, indicating perceived organizational robustness, clinician culture and management support; and greater perceived patient needs and their likely benefit from SBIRT, had higher BI rates.</div></div><div><h3>Conclusions</h3><div>Results provide information on factors which may facilitate successful ASBI implementation and sustainability and could inform future ASBI implementation efforts in healthcare system settings. In particular, efforts toward bolstering an organization's implementation infrastructure capacity, prior to embarking on implementation of a systematic ASBI program, could potentially help pave the way for successful implementation.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring heterogeneity in recovery from substance use disorder following mindfulness-based relapse prevention: A latent profile analysis. 探索以正念为基础的复发预防后药物使用障碍康复的异质性:潜在特征分析
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-08 DOI: 10.1016/j.josat.2024.209537
David I K Moniz-Lewis, Katie Witkiewitz

Introduction: Substance use disorder (SUD) recovery is heterogeneous. Yet, over the last 50 years, substance use treatment providers and researchers have often defined success as sustained abstinence from substance use. An often overlooked but equally valid pathway to recovery for persons with SUD is non-abstinent recovery. However, most of the literature on non-abstinent recovery exists for individuals with alcohol use disorder (AUD) with few studies of non-abstinent recovery for other types of SUD. Literature exploring the mechanisms that lead to non-abstinent recovery is also lacking. As such, the current study aimed to examine recovery profiles for individuals (N = 454) recruited in two randomized clinical trials comparing mindfulness-based relapse prevention with cognitive-behavioral relapse prevention and/or treatment as usual.

Methods: Latent profile analysis empirically derived profiles of recovery following outpatient aftercare SUD treatment. Multinomial logistic regression examined associations between treatment assignment and recovery profile, including potential psychological mediators (e.g., mindfulness) and contextual moderators (e.g., annual household income).

Results: Analyses supported four recovery profiles: (1) low-functioning frequent substance use; (2) low-functioning infrequent substance use; (3) high-functioning frequent substance use; (4) high-functioning infrequent substance use. There were no significant interaction effects of race or ethnicity by treatment type, or household income by treatment type, in predicting recovery profiles. Trait mindfulness, craving, and psychological flexibility failed to mediate the association between treatment assignment and recovery profile; however, there were statistically significant differences in trait mindfulness with individuals expected to be classified in the low-functioning infrequent substance use profile showing significantly lower levels of trait mindfulness compared to individuals in the two high-functioning profiles.

Conclusions: Findings suggest that recovery from SUD is heterogeneous, and profiles of recovery based on dimensions of substance use and functioning can be identified across a variety of SUD, including among people with co-occurring SUD. Additionally, trait mindfulness appears to be a differentiating factor across recovery profiles. Further research is needed to explore how psychological and social factors may moderate and influence both abstinent and non-abstinent forms of recovery.

导言:药物使用障碍(SUD)的康复是多种多样的。然而,在过去的 50 年里,药物使用治疗提供者和研究人员通常将成功定义为持续戒断药物使用。对于 SUD 患者来说,一个经常被忽视但同样有效的康复途径是非禁欲康复。然而,大多数关于非禁欲康复的文献都是针对酒精使用障碍(AUD)患者的,对其他类型 SUD 的非禁欲康复研究很少。探讨导致非脱瘾康复的机制的文献也很缺乏。因此,本研究旨在研究在两项随机临床试验中招募的患者(N = 454)的康复特征,这两项试验比较了正念预防复发与认知行为预防复发和/或常规治疗:方法:通过潜特征分析,根据经验推导出门诊后护理 SUD 治疗后的康复特征。多项式逻辑回归研究了治疗分配与康复特征之间的关联,包括潜在的心理调解因素(如正念)和环境调节因素(如家庭年收入):分析支持四种康复特征:(1)低功能频繁使用药物;(2)低功能不频繁使用药物;(3)高功能频繁使用药物;(4)高功能不频繁使用药物。在预测康复情况时,治疗类型对种族或民族的交互影响以及治疗类型对家庭收入的交互影响均不明显。特质正念、渴求和心理灵活性未能调节治疗分配与康复情况之间的关系;然而,特质正念存在统计学意义上的显著差异,与两个高功能情况下的个人相比,预计被归类为低功能不经常使用药物情况下的个人的特质正念水平明显较低:研究结果表明,从药物依赖性精神疾病中恢复是多方面的,基于药物使用和功能层面的恢复特征可以在各种药物依赖性精神疾病中识别,包括在共患药物依赖性精神疾病的人群中识别。此外,特质正念似乎是区分不同康复特征的一个因素。还需要进一步的研究来探索心理和社会因素如何调节和影响戒断和非戒断形式的康复。
{"title":"Exploring heterogeneity in recovery from substance use disorder following mindfulness-based relapse prevention: A latent profile analysis.","authors":"David I K Moniz-Lewis, Katie Witkiewitz","doi":"10.1016/j.josat.2024.209537","DOIUrl":"https://doi.org/10.1016/j.josat.2024.209537","url":null,"abstract":"<p><strong>Introduction: </strong>Substance use disorder (SUD) recovery is heterogeneous. Yet, over the last 50 years, substance use treatment providers and researchers have often defined success as sustained abstinence from substance use. An often overlooked but equally valid pathway to recovery for persons with SUD is non-abstinent recovery. However, most of the literature on non-abstinent recovery exists for individuals with alcohol use disorder (AUD) with few studies of non-abstinent recovery for other types of SUD. Literature exploring the mechanisms that lead to non-abstinent recovery is also lacking. As such, the current study aimed to examine recovery profiles for individuals (N = 454) recruited in two randomized clinical trials comparing mindfulness-based relapse prevention with cognitive-behavioral relapse prevention and/or treatment as usual.</p><p><strong>Methods: </strong>Latent profile analysis empirically derived profiles of recovery following outpatient aftercare SUD treatment. Multinomial logistic regression examined associations between treatment assignment and recovery profile, including potential psychological mediators (e.g., mindfulness) and contextual moderators (e.g., annual household income).</p><p><strong>Results: </strong>Analyses supported four recovery profiles: (1) low-functioning frequent substance use; (2) low-functioning infrequent substance use; (3) high-functioning frequent substance use; (4) high-functioning infrequent substance use. There were no significant interaction effects of race or ethnicity by treatment type, or household income by treatment type, in predicting recovery profiles. Trait mindfulness, craving, and psychological flexibility failed to mediate the association between treatment assignment and recovery profile; however, there were statistically significant differences in trait mindfulness with individuals expected to be classified in the low-functioning infrequent substance use profile showing significantly lower levels of trait mindfulness compared to individuals in the two high-functioning profiles.</p><p><strong>Conclusions: </strong>Findings suggest that recovery from SUD is heterogeneous, and profiles of recovery based on dimensions of substance use and functioning can be identified across a variety of SUD, including among people with co-occurring SUD. Additionally, trait mindfulness appears to be a differentiating factor across recovery profiles. Further research is needed to explore how psychological and social factors may moderate and influence both abstinent and non-abstinent forms of recovery.</p>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Was receipt of any specialty alcohol treatment during the pandemic effective at reducing drinking for patients with or at risk of AUD? 在大流行期间,接受任何特殊酒精治疗是否能有效减少 AUD 患者或有 AUD 风险的患者的饮酒量?
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-06 DOI: 10.1016/j.josat.2024.209531
Andrea H Kline-Simon, Vanessa A Palzes, Felicia W Chi, Derek D Satre, Constance Weisner, Stacy Sterling

Introduction: The COVID-19 pandemic changed the way healthcare providers delivered most health services, including treatment for alcohol use disorder (AUD). Specialty alcohol treatment remained available through the pandemic, and within some systems treatment use increased likely due to telehealth availability. However, the field knows little about the relationship between the pandemic's expanded access to specialty alcohol treatment and alcohol use outcomes.

Methods: The sample included 14,712 patients from Kaiser Permanente Northern California who screened positive for unhealthy alcohol use in primary care and had an AUD diagnosis or risked developing an AUD by reporting 5 or more heavy drinking days in a 3-month period between 1/1/2019 and 2/29/2020 (pre-pandemic). The study examined the receipt of any specialty alcohol treatment (including at least one outpatient, inpatient, or telehealth specialty treatment encounter, or pharmacotherapy prescription) from 3/1/2020 (pandemic start) to either the first completed follow-up alcohol screening or 6/20/2022 (study period end). The outcomes of alcohol use included changes in heavy drinking days, drinks per week, drinking days per week, and drinks per drinking day between the pre- and post-pandemic periods.

Results: On average patients significantly decreased alcohol use across all four alcohol use measures examined, regardless of whether they received treatment. However, those who received any treatment compared to those who did not have greater reductions in alcohol use, with an additional decrease of -3.55 heavy drinking days (95 % CI = -5.93, -1.17), -3.80 drinks per week (95 % CI = -5.18, -2.42), -0.72 drinks per drinking day (95 % CI = -1.14, -0.30), and - 1.01 drinking days per week (95 % CI = -1.30, -0.72). Treatment effects were greatest among patients who exceeded both daily and weekly limits pre-pandemic, with an additional decrease of -10.75 heavy drinking days (95 % CI = -15.28, -6.21), -12.83 drinks per week (95 % CI = -16.31, -9.35), -1.67 drinks per drinking day (95 % CI = -2.19, -1.14), and -2.02 drinking days per week (95 % CI = -2.41, -1.63).

Conclusions: On average, patients decreased alcohol use during the onset of the pandemic, however, those who had any specialty alcohol treatment had significantly greater decreases, suggesting that the hybrid in-person and telehealth treatment approach was effective during the pandemic.

导言:COVID-19 大流行改变了医疗服务提供者提供大多数医疗服务的方式,包括酒精使用障碍 (AUD) 的治疗。大流行期间仍可提供专业酒精治疗,在某些系统中,可能由于远程医疗的可用性,治疗使用率有所增加。然而,该领域对大流行病扩大了专业酒精治疗的可及性与酒精使用结果之间的关系知之甚少:样本包括 14,712 名来自北加州凯泽医疗集团(Kaiser Permanente Northern California)的患者,这些患者在初级保健中被筛查出不健康饮酒,并被诊断为 AUD,或在 2019 年 1 月 1 日至 2020 年 2 月 29 日(大流行前)的 3 个月内报告有 5 天或 5 天以上大量饮酒的风险。该研究调查了自 2020 年 3 月 1 日(大流行开始)至首次完成酒精筛查随访或 2022 年 6 月 20 日(研究期结束)期间接受任何专业酒精治疗的情况(包括至少一次门诊、住院或远程医疗专业治疗或药物治疗处方)。饮酒结果包括大流行前和大流行后期间大量饮酒天数、每周饮酒天数、每周饮酒天数和每天饮酒天数的变化:无论是否接受治疗,患者在所有四项酒精使用指标上的平均饮酒量都有明显下降。然而,与未接受治疗的患者相比,接受过任何治疗的患者饮酒量减少得更多,大量饮酒天数减少了-3.55天(95 % CI = -5.93,-1.17),每周饮酒量减少了-3.80杯(95 % CI = -5.18,-2.42),每天饮酒量减少了-0.72杯(95 % CI = -1.14,-0.30),每周饮酒天数减少了-1.01天(95 % CI = -1.30,-0.72)。在大流行前每日和每周饮酒量均超标的患者中,治疗效果最好,额外减少了-10.75个大量饮酒日(95 % CI = -15.28,-6.21)、每周-12.83杯酒(95 % CI = -16.31,-9.35)、每天-1.67杯酒(95 % CI = -2.19,-1.14)和每周-2.02个饮酒日(95 % CI = -2.41,-1.63):平均而言,患者在大流行期间减少了饮酒量,然而,接受过专业酒精治疗的患者饮酒量明显减少,这表明在大流行期间,面对面和远程医疗的混合治疗方法是有效的。
{"title":"Was receipt of any specialty alcohol treatment during the pandemic effective at reducing drinking for patients with or at risk of AUD?","authors":"Andrea H Kline-Simon, Vanessa A Palzes, Felicia W Chi, Derek D Satre, Constance Weisner, Stacy Sterling","doi":"10.1016/j.josat.2024.209531","DOIUrl":"https://doi.org/10.1016/j.josat.2024.209531","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic changed the way healthcare providers delivered most health services, including treatment for alcohol use disorder (AUD). Specialty alcohol treatment remained available through the pandemic, and within some systems treatment use increased likely due to telehealth availability. However, the field knows little about the relationship between the pandemic's expanded access to specialty alcohol treatment and alcohol use outcomes.</p><p><strong>Methods: </strong>The sample included 14,712 patients from Kaiser Permanente Northern California who screened positive for unhealthy alcohol use in primary care and had an AUD diagnosis or risked developing an AUD by reporting 5 or more heavy drinking days in a 3-month period between 1/1/2019 and 2/29/2020 (pre-pandemic). The study examined the receipt of any specialty alcohol treatment (including at least one outpatient, inpatient, or telehealth specialty treatment encounter, or pharmacotherapy prescription) from 3/1/2020 (pandemic start) to either the first completed follow-up alcohol screening or 6/20/2022 (study period end). The outcomes of alcohol use included changes in heavy drinking days, drinks per week, drinking days per week, and drinks per drinking day between the pre- and post-pandemic periods.</p><p><strong>Results: </strong>On average patients significantly decreased alcohol use across all four alcohol use measures examined, regardless of whether they received treatment. However, those who received any treatment compared to those who did not have greater reductions in alcohol use, with an additional decrease of -3.55 heavy drinking days (95 % CI = -5.93, -1.17), -3.80 drinks per week (95 % CI = -5.18, -2.42), -0.72 drinks per drinking day (95 % CI = -1.14, -0.30), and - 1.01 drinking days per week (95 % CI = -1.30, -0.72). Treatment effects were greatest among patients who exceeded both daily and weekly limits pre-pandemic, with an additional decrease of -10.75 heavy drinking days (95 % CI = -15.28, -6.21), -12.83 drinks per week (95 % CI = -16.31, -9.35), -1.67 drinks per drinking day (95 % CI = -2.19, -1.14), and -2.02 drinking days per week (95 % CI = -2.41, -1.63).</p><p><strong>Conclusions: </strong>On average, patients decreased alcohol use during the onset of the pandemic, however, those who had any specialty alcohol treatment had significantly greater decreases, suggesting that the hybrid in-person and telehealth treatment approach was effective during the pandemic.</p>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey 南佛罗里达州康复住所对丁丙诺啡的接受程度有限:秘密顾客调查。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-05 DOI: 10.1016/j.josat.2024.209535

Background

Buprenorphine is a first-line treatment for opioid use disorder (OUD), essential for reducing opioid overdose mortality and improving treatment retention. Despite federal policies that mandate the acceptance of buprenorphine in recovery residences, individuals in South Florida taking this medication often face significant barriers to admission. This study uses a secret shopper survey to examine whether federal policies regarding prescribed buprenorphine use are being violated in South Florida recovery residences.

Methods

We selected recovery residences in South Florida due to the region's high opioid overdose death rate and its prominence as a recovery hub. From a list of 141 Florida Association of Recovery Residences (FARR)-certified residences in Palm Beach, Broward, and Miami-Dade, we randomly surveyed 100 programs across all treatment levels (I-IV) using a standardized script. The primary outcome was whether residences accepted individuals taking buprenorphine, classified into three categories: (1) unconditional acceptance, where any person taking buprenorphine was accepted; (2) denial, where admission was refused for all individuals taking buprenorphine; and (3) conditional acceptance, where admission was granted under specific conditions. Secondary outcomes included requirements for conditional acceptance, such as dose limits or tapering policies.

Results

The distribution of the 100 surveyed recovery residences was comparable to the 141 FARR-certified facilities: 67 % were in Palm Beach, 31 % in Broward, and 2 % in Miami-Dade. Most residences (55 %) were level II certified, followed by 26 % level IV, 14 % level I, and 5 % level III. Sixteen percent of residences permitted admission of individuals taking any buprenorphine dose, 31 % had conditional policies, and 53 % prohibited buprenorphine. The maximum acceptance across all counties and levels was 20 %. No significant differences were observed by county (p = 0.61) or facility level (p = 0.29). Of 31 residences with conditional policies, 25.8 % (n = 8) required a mandatory taper, 38.7 % (n = 12) allowed a maximum 8 mg daily dosage, 12.9 % (n = 4) had a maximum 12 mg daily dosage, 6.5 % (n = 2) had a maximum 16 mg daily dosage, 6.5 % (n = 2) required a provider letter, and 9.7 % (n = 3) did not provide further information.

Conclusions

Access to FARR-certified recovery residences is severely limited for individuals in South Florida taking buprenorphine. Urgent action is needed to improve access to evidence-based OUD treatments, address complexities influencing recovery residence policy and practice, and ensure appropriate allocation of public funds like State Opioid Response dollars.
背景:丁丙诺啡是治疗阿片类药物使用障碍(OUD)的一线疗法,对于降低阿片类药物过量死亡率和提高治疗持续率至关重要。尽管联邦政策规定康复机构必须接受丁丙诺啡,但在南佛罗里达州,服用这种药物的人在入院治疗时往往面临巨大障碍。本研究采用秘密购物者调查的方式,考察南佛罗里达州的康复机构是否违反了有关丁丙诺啡处方使用的联邦政策:我们选择了南佛罗里达州的康复机构,因为该地区阿片类药物过量致死率高,而且是康复中心。从棕榈滩、布劳沃德和迈阿密-戴德的 141 家经佛罗里达康复机构协会 (FARR) 认证的康复机构名单中,我们使用标准化脚本随机调查了所有治疗级别(I-IV)的 100 个项目。主要结果是治疗机构是否接受服用丁丙诺啡的个人,分为三类:(1)无条件接受,即接受任何服用丁丙诺啡的人;(2)拒绝,即拒绝所有服用丁丙诺啡的人;(3)有条件接受,即在特定条件下允许接受。次要结果包括有条件接受的要求,如剂量限制或减量政策:接受调查的 100 家康复机构的分布情况与 141 家获得 FARR 认证的机构相当:棕榈滩占 67%,布劳沃德占 31%,迈阿密-戴德占 2%。大多数疗养院(55%)都获得了二级认证,其次是 26%的四级疗养院、14%的一级疗养院和 5%的三级疗养院。16% 的戒毒所允许服用任何丁丙诺啡剂量的患者入住,31% 的戒毒所制定了有条件的政策,53% 的戒毒所禁止服用丁丙诺啡。在所有县和级别中,最大接受率为 20%。各县(p = 0.61)或机构级别(p = 0.29)之间没有明显差异。在 31 家制定了有条件政策的机构中,25.8%(n = 8)要求强制减量,38.7%(n = 12)允许每天最大用量为 8 毫克,12.9%(n = 4)每天最大用量为 12 毫克,6.5%(n = 2)每天最大用量为 16 毫克,6.5%(n = 2)需要提供者信函,9.7%(n = 3)未提供进一步信息:结论:对于南佛罗里达州服用丁丙诺啡的人来说,获得 FARR 认证的康复住所的机会非常有限。我们需要采取紧急行动,改善获得循证 OUD 治疗的机会,解决影响康复住所政策和实践的复杂问题,并确保州阿片类药物应对资金等公共资金的合理分配。
{"title":"Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey","authors":"","doi":"10.1016/j.josat.2024.209535","DOIUrl":"10.1016/j.josat.2024.209535","url":null,"abstract":"<div><h3>Background</h3><div>Buprenorphine is a first-line treatment for opioid use disorder (OUD), essential for reducing opioid overdose mortality and improving treatment retention. Despite federal policies that mandate the acceptance of buprenorphine in recovery residences, individuals in South Florida taking this medication often face significant barriers to admission. This study uses a secret shopper survey to examine whether federal policies regarding prescribed buprenorphine use are being violated in South Florida recovery residences.</div></div><div><h3>Methods</h3><div>We selected recovery residences in South Florida due to the region's high opioid overdose death rate and its prominence as a recovery hub. From a list of 141 Florida Association of Recovery Residences (FARR)-certified residences in Palm Beach, Broward, and Miami-Dade, we randomly surveyed 100 programs across all treatment levels (I-IV) using a standardized script. The primary outcome was whether residences accepted individuals taking buprenorphine, classified into three categories: (1) unconditional acceptance, where any person taking buprenorphine was accepted; (2) denial, where admission was refused for all individuals taking buprenorphine; and (3) conditional acceptance, where admission was granted under specific conditions. Secondary outcomes included requirements for conditional acceptance, such as dose limits or tapering policies.</div></div><div><h3>Results</h3><div>The distribution of the 100 surveyed recovery residences was comparable to the 141 FARR-certified facilities: 67 % were in Palm Beach, 31 % in Broward, and 2 % in Miami-Dade. Most residences (55 %) were level II certified, followed by 26 % level IV, 14 % level I, and 5 % level III. Sixteen percent of residences permitted admission of individuals taking any buprenorphine dose, 31 % had conditional policies, and 53 % prohibited buprenorphine. The maximum acceptance across all counties and levels was 20 %. No significant differences were observed by county (<em>p</em> = 0.61) or facility level (<em>p</em> = 0.29). Of 31 residences with conditional policies, 25.8 % (<em>n</em> = 8) required a mandatory taper, 38.7 % (<em>n</em> = 12) allowed a maximum 8 mg daily dosage, 12.9 % (<em>n</em> = 4) had a maximum 12 mg daily dosage, 6.5 % (<em>n</em> = 2) had a maximum 16 mg daily dosage, 6.5 % (<em>n</em> = 2) required a provider letter, and 9.7 % (<em>n</em> = 3) did not provide further information.</div></div><div><h3>Conclusions</h3><div>Access to FARR-certified recovery residences is severely limited for individuals in South Florida taking buprenorphine. Urgent action is needed to improve access to evidence-based OUD treatments, address complexities influencing recovery residence policy and practice, and ensure appropriate allocation of public funds like State Opioid Response dollars.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvement in coping skills from culturally-adapted digital CBT for Spanish-speaking Hispanics with substance use disorder: Secondary analysis of a randomized clinical trial 针对患有药物使用障碍的西班牙语西班牙裔患者的文化适应性数字 CBT 改善了他们的应对技能:随机临床试验的二次分析。
0 PSYCHOLOGY, CLINICAL Pub Date : 2024-10-05 DOI: 10.1016/j.josat.2024.209536

Introduction

Developing adaptive coping skills for avoiding substance use is a proposed treatment mechanism of cognitive behavioral therapy (CBT) for substance use disorder (SUD). However, the generalizability of research on treatment mechanisms of CBT for SUD is limited by the underrepresentation of racial/ethnic minorities in clinical trials. In a secondary analysis of clinical trial data, we tested whether a culturally-adapted digital CBT program for Hispanics (“Spanish CBT4CBT”) improved the quality of coping skills for avoiding substance use. We also tested whether coping skills' quality was associated with reductions in primary substance use.

Methods

Participants were Spanish-speaking Hispanic adults seeking outpatient treatment for SUD (n = 85; 68 % male; primary substance type: 36 % cannabis, 33 % alcohol, 26 % cocaine, 5 % other). They were randomized to 8 weeks of outpatient treatment as usual (TAU) or TAU + Spanish CBT4CBT and assessed for 6 months after treatment. The study conducted separate analyses for the full sample (n = 85) and for those who engaged in at least 5 treatment sessions (“treatment exposed”; n = 64). Daily substance use and coping skills' quality were assessed repeatedly during the treatment and follow-up periods. Bayesian mixed models for repeated measures tested hypotheses.

Results

Among treatment-exposed participants, those receiving TAU + Spanish CBT4CBT improved the quality of coping skills more than TAU alone during the treatment period (b = 0.77; 95 % CI[0.08, 1.47]), but this difference was not detected during the follow-up period. In the full sample and treatment exposed subsample, participants with higher quality coping skills during the study reported less primary substance use (b = −0.67; 95 % CI[−1.08, −0.26]). Among treatment-exposed participants only, within-person increases in the quality of coping skills were associated with reductions in future primary substance use (b = −0.18; 95 % CI[−0.36, −0.01]).

Conclusions

Spanish-speaking Hispanics with SUD may improve the quality of their coping skills more when they are sufficiently exposed to a culturally-adapted digital CBT program during outpatient treatment. Coping skills' quality may be a mechanism of CBT for SUD among Hispanic populations. Spanish-speaking Hispanics' access to treatments that target mechanisms of behavior change may be expanded by digital therapeutics.
简介:培养避免使用药物的适应性应对技能是认知行为疗法(CBT)治疗药物使用障碍(SUD)的一种治疗机制。然而,由于少数种族/族裔在临床试验中的代表性不足,有关认知行为疗法治疗药物使用障碍的治疗机制的研究的推广性受到了限制。在对临床试验数据的二次分析中,我们测试了针对西班牙裔的文化适应性数字 CBT 项目("西班牙语 CBT4CBT")是否提高了避免药物使用的应对技能的质量。我们还测试了应对技能的质量是否与主要药物使用的减少有关:方法:参与者均为讲西班牙语、寻求门诊治疗 SUD 的成人(n = 85;68 % 为男性;主要药物类型:36 % 为大麻,33 % 为毒品):大麻 36%,酒精 33%,可卡因 26%,其他 5%)。他们被随机分配接受为期 8 周的门诊常规治疗(TAU)或 TAU + 西班牙语 CBT4CBT,并在治疗后接受 6 个月的评估。该研究对全部样本(n = 85)和至少接受了 5 次治疗的样本("接受治疗者";n = 64)进行了单独分析。在治疗和随访期间,对日常药物使用和应对技能的质量进行了反复评估。贝叶斯重复测量混合模型对假设进行了检验:结果:在接受治疗的参与者中,接受TAU+西班牙CBT4CBT治疗的参与者在治疗期间比单独接受TAU治疗的参与者更能提高应对技能的质量(b = 0.77; 95 % CI[0.08,1.47]),但在随访期间未发现这一差异。在全部样本和接受治疗的子样本中,研究期间应对技能质量较高的参与者报告的初次药物使用较少(b = -0.67;95 % CI[-1.08,-0.26])。仅在接受治疗的参与者中,应对技能质量的个人内部提高与未来初级药物使用的减少有关(b = -0.18;95 % CI[-0.36,-0.01]):结论:讲西班牙语的西班牙裔 SUD 患者在门诊治疗期间充分接触适应文化的数字化 CBT 项目后,应对技能的质量可能会有更大的提高。应对技能的质量可能是西语裔人群中治疗 SUD 的 CBT 的一个机制。讲西班牙语的拉美人接受以行为改变机制为目标的治疗的机会可能会因数字疗法而扩大。
{"title":"Improvement in coping skills from culturally-adapted digital CBT for Spanish-speaking Hispanics with substance use disorder: Secondary analysis of a randomized clinical trial","authors":"","doi":"10.1016/j.josat.2024.209536","DOIUrl":"10.1016/j.josat.2024.209536","url":null,"abstract":"<div><h3>Introduction</h3><div>Developing adaptive coping skills for avoiding substance use is a proposed treatment mechanism of cognitive behavioral therapy (CBT) for substance use disorder (SUD). However, the generalizability of research on treatment mechanisms of CBT for SUD is limited by the underrepresentation of racial/ethnic minorities in clinical trials. In a secondary analysis of clinical trial data, we tested whether a culturally-adapted digital CBT program for Hispanics (“Spanish CBT4CBT”) improved the quality of coping skills for avoiding substance use. We also tested whether coping skills' quality was associated with reductions in primary substance use.</div></div><div><h3>Methods</h3><div>Participants were Spanish-speaking Hispanic adults seeking outpatient treatment for SUD (<em>n</em> = 85; 68 % male; primary substance type: 36 % cannabis, 33 % alcohol, 26 % cocaine, 5 % other). They were randomized to 8 weeks of outpatient treatment as usual (TAU) or TAU + Spanish CBT4CBT and assessed for 6 months after treatment. The study conducted separate analyses for the full sample (<em>n</em> = 85) and for those who engaged in at least 5 treatment sessions (“treatment exposed”; <em>n</em> = 64). Daily substance use and coping skills' quality were assessed repeatedly during the treatment and follow-up periods. Bayesian mixed models for repeated measures tested hypotheses.</div></div><div><h3>Results</h3><div>Among treatment-exposed participants, those receiving TAU + Spanish CBT4CBT improved the quality of coping skills more than TAU alone during the treatment period (<em>b</em> = 0.77; 95 % CI[0.08, 1.47]), but this difference was not detected during the follow-up period. In the full sample and treatment exposed subsample, participants with higher quality coping skills during the study reported less primary substance use (<em>b</em> = −0.67; 95 % CI[−1.08, −0.26]). Among treatment-exposed participants only, within-person increases in the quality of coping skills were associated with reductions in future primary substance use (<em>b</em> = −0.18; 95 % CI[−0.36, −0.01]).</div></div><div><h3>Conclusions</h3><div>Spanish-speaking Hispanics with SUD may improve the quality of their coping skills more when they are sufficiently exposed to a culturally-adapted digital CBT program during outpatient treatment. Coping skills' quality may be a mechanism of CBT for SUD among Hispanic populations. Spanish-speaking Hispanics' access to treatments that target mechanisms of behavior change may be expanded by digital therapeutics.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of substance use and addiction treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1